PATENT CLAIM ANALYSIS

Application Number: 15986369
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "093410"]

Abstract:
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria  Clostridium scindens  and/or the bacteria  Blautia producta  contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of  Clostridium scindens.

Claim (Index 33):
The composition of  claim 21 , wherein the composition is formulated for oral, nasogastric, or rectal administration.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 93.0
- Lexical Diversity: 1.4375
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15884029', '15039007', '14968086', '15630088', '15801783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7170080258158247
- 35 USC 102 Novelty (BERT): 0.530968496827231
- Combined Prediction Score: 0.6984040729169654
- Mean Citation Score: 318.505716
- Max Citation Score: 346.61725
- Similarity Product: 217.229012434274

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test